Aptamer Group (LSE:APTA) lifted revenue by 28% to £1.54m in the year to 30 June 2026 and narrowed its loss for the year to £1.86m, helped by a larger tax credit. The board said year-end cash of £4.36m provides runway into calendar 2028, although the accounts also disclose a material uncertainty over going concern.
What was announced
AIM-quoted Aptamer Group plc, which develops Optimer binders and works with pharmaceutical, diagnostics and life sciences customers on R&D and licensing programmes, published final results for the twelve months ended 30 June 2026 on 13 October 2026.
Revenue rose 28% to £1,544k (2025: £1,203k), of which licensing contributed £101k and the remainder came from R&D services. Chief Executive Dr Arron Tolley said: "This has been a year of inflection for Aptamer."
The numbers
Gross profit increased to £822k from £579k, which on our calculation implies a gross margin of about 53%, up from about 48%. The adjusted EBITDA loss widened slightly to £2,340k (2025: £2,193k), and the loss before tax was £2,787k (2025: £2,569k).
The loss for the year narrowed to £1,862k from £2,424k because of a tax credit of £925k (2025: £145k). That credit comprised £447k relating to the current year and £478k relating to prior periods, which the notes attribute to an updated R&D claim. Basic and diluted loss per share was 0.07p (0.14p).
Cash at 30 June 2026 was £4,358k, compared with £1,059k a year earlier, following a share placing in spring 2026 that generated about £4.1m net. The board said the cash position "provides runway into calendar 2028", stating that this is before any further licensing receipts. The sales pipeline stood at £7.0m on 21 September 2026, up from £4.8m at 30 June 2026. A pipeline represents potential rather than contracted business.
Going concern and commercial progress
Despite the runway statement, the directors said that "the above factors give rise to a material uncertainty which may cast significant doubt" on the group's ability to continue as a going concern. The auditor's report was unqualified but referred to this material uncertainty. The directors noted that a downside scenario could require additional funding, which may not be available.
On the commercial side, Aptamer out-licensed enzyme-modulating Optimers to Twist Bioscience and Alphazyme, with terms including upfront payments, royalties and reagent supply revenue; first licensing payments have been received. A Gates Foundation-supported programme is developing folic acid Optimers into a rapid test for food fortification, and an immunohistochemistry reagent developed for a global life sciences company carries a 2% royalty on net sales, subject to validation.
A top five pharmaceutical partner awarded more than £0.75m of new contracts, taking lifetime value with that customer above £1m, and the group signed its first radioligand therapy contract, worth £360,000, with a top three global pharmaceutical company. The second development phase of a Unilever programme was completed in-house. After the period end, multi-year master service agreements with several top 20 pharmaceutical companies were described as being in advanced negotiation; these had not been signed at the time of the announcement. Cavendish Capital Markets has been appointed joint broker alongside Turner Pope Investments.
What to watch next
The board described a materially changed business and said it expects growth to continue, stating: "The prospects for Aptamer in 2027 and beyond remain very encouraging." No numerical revenue or profit guidance was provided.
Points to monitor include conversion of the £7.0m pipeline into contracted revenue, the outcome of the master service agreement negotiations, further licensing receipts and cash consumption relative to the stated runway. The AGM date was not identified in the announcement text reviewed.






Please wait processing your request...